PLEASANTON, Calif., March 18, 2013 /PRNewswire/ — Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support, and restore failing hearts, announced today that it has successfully completed the first human use of HeartMate PHP…
First Human Use For Thoratec’s HeartMate PHP™
Thoratec has successfully completed the first human use of HeartMate PHP (Percutaneous Heart Pump). The first PHP patient was supported for over 60 minutes during a high-risk percutaneous coronary intervention.